Biodexa Pharmaceuticals

BDRX

時価総額 $46.9万

October 13, 2026 Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP Update on expected timing of pre-specified futility analysis and database lock Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has enrolled 100 patients in its registrational Phase 3 trial of eRapa in Familial Adenomatous Polyposis (FAP), NCT06950385. The trial, branded “Serenta” is recruiting at 29 clinical sites across the US and five countries in Europe with a further two sites in Canada expected to be initiated shortly.

Today's interview with Stephen Stamp, CEO of Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) is about the Company's lead program, eRapa in Familial Adenomatous Polyposis (FAP), a genetic disease of the lower GI tract for which the only current remedy is surgical removal of the colon and/or rectum. Key takeaways: eRapa is an oral drug candidate designed to reduce or eliminate the need for surgical treatments; a Phase 3 registrational trial, running at 29 U.S. and EU centers, is more than 50 percent enrolled; an interim futility analysis is expected in Q1 2027; FDA and EMA Orphan Drug designations are complemented by $20 million in grant funding from Texas-based CPRIT.

Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds September 15, 2026 Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced that it has entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants to purchase an aggregate of 2,204,218 American Depositary Shares (“ADSs”) of the Company (the “Existing Warrants”) at an exercise price of $1.05 for gross cash proceeds of approximately $2.3 million, before deducting financial advisor fees and other transaction expenses. The ADSs issuable upon the exercise of the existing warrants have been registered pursuant to an effective registration statement on Form F-1, as amended (File No.

U.S. stock futures were lower this morning, with the Nasdaq 100 futures falling around 500 points on Monday.

September 11, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2026 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, today announces its unaudited interim results for the six months ended June 30, 2026 which will also be made available on the Company's website at https://biodexapharma.com/ . OPERATIONAL HIGHLIGHTS The Company announced the following in the six months ended June 30, 2026: In-license of MTX240 (formerly OPB-171755) from Otsuka Pharmaceutical Co., Limited in February 2026 with a nominal upfront payment.

August 19, 2026 Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP 87 subjects, over 50% of target, recruited Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has exceeded the half-way point in the recruitment of subjects in its registrational Phase 3 trial of eRapa in Familial Adenomatous Polyposis (FAP), NCT06950385. As of today, 87 of a planned 168 subjects have been recruited into the Serenta trial.

July 29, 2026 Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces that at its General Meeting held earlier today, all four resolutions put to the Company's shareholders were duly passed. The full text of, inter alia, the resolutions proposed and passed at the General Meeting can be found in the Notice of the General Meeting on the Company's website at: https://biodexapharma.com/investors/corporate-governance/#agms.

July 28, 2026 Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has held its first round table meeting in Paris, France as part of expanding its support for Familial Adenomatous Polyposis (FAP) patients and prescribers. The sharing of experience and expertise amongst patients, patient advocacy groups and clinicians is informing Biodexa's goal of improving outcomes and quality of life for FAP patients.

June 30, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of Annual General Meeting Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers announces that its re-scheduled Annual General Meeting held at 11.00 BST today, ordinary resolutions 1 through 7 passed with majorities of 94%, 73%, 92%, 81%, 81%, 91% and 94%, respectively. Ordinary resolution 8 and special resolution 10 failed to pass.

June 30, 2026 Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the pricing of a $0.8 million registered offering (the “Registered Offering”), a $1.0 million concurrent private placement (the “Private Offering”) and a $1.7 million warrant inducement (the “Warrant Inducement” and, together with the Registered Offering and the Private Offering, the “Offerings”) utilizing existing share capital authorities. The Registered Offering consists of 282,952 American depositary shares (“ADSs”) (or pre-funded warrants in lieu thereof) at an offering price of $2.85 per ADS.